Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 18/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.85 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20007585 | 1.00 | TRPV4 (0.85) | TRPV4CYP3A4KCNH2SLC22A12 | |
| SCHEMBL20007450 | 0.93 | TRPV4 (0.84) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL30266300 | 0.93 | TRPV4 (0.84) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL19995625 | 0.93 | TRPV4 (0.84) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL20007725 | 0.92 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL19995382 | 0.92 | TRPV4 (0.82) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL21172110 | 0.92 | TRPV4 (0.82) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL20007723 | 0.92 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL20007454 | 0.92 | TRPV4 (0.82) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL29355181 | 0.92 | TRPV4 (0.82) | TRPV4CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | claimed |
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588891-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.